PHARMACOKINETIC COMPARISON OF NEORAL TO ABBOTT CYCLOSPORINE

NEORAL 与雅培环孢素的药代动力学比较

• 批准号: 6307416
• 负责人: TIMOTHY L PRUETT
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307416
• 关键词: clinical research; cyclosporines; drug design /synthesis /production; gastrointestinal drug absorption; human subject; pharmacokinetics; transplantation immunology

Organ transplant recipients take expensive immunosuppressive medications for life. At the present time, cyclosporine (Neoral) is only available from one manufacturer and costs $500 to $1000 a month. The release of a generic cyclosporine would greatly benefit the transplant community. Because of a history of erratic drug absorption, for a generic cyclosporine to be clinically competive, pharmacokinetic characteristics should closely resemble those of Neoral.

器官移植受者终身服用昂贵的免疫抑制药物。目前，环孢素(Neole)只能从一家制造商获得，每月费用为500至1000美元。通用环孢素的释放将极大地造福于移植社区。由于药物吸收不稳定的历史，要使普通环孢素在临床上具有竞争力，其药代动力学特征应与新奥来的相似。